pembrolizumab
merck
['melanoma', 'pembro']
and on there other hand -#adjuvant pembro for the same stage iib/c #melanoma shows not all subgroups benefit. non-nodular and non-ulcerated primary being the most interesting ones. should we start tailoring our tx based on a personal high risk clinical profile?#smr2022 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials